Diabetic Ulcer Treatment Market Size, Share and Covid-19 Impact Analysis, By Ulcer Type (Foot Ulcer (Neuropathic Ulcer, Ischemic Ulcer, and Neuro-ischemic Ulcer), Mouth Ulcer, and Others), By Treatment Type (Wound-care Dressings, Wound-care Devices, Active Therapies, and Others), By End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Homecare Settings), and Regional Forecast, 2020-2032

The global diabetic ulcer treatment market size was USD 8.32 billion in 2019 and is projected to reach USD 18.41 billion by 2032, exhibiting a CAGR of 6.4% during the forecast period.

The rise in prevalence of diabetes and the rise in the adoption of wound care devices for the treatment of diabetic ulcers are the key factors responsible for elevating this market growth during the forecast period. According to a research study by the Diabetes Care published on NCBI, the global prevalence of diabetic foot ulcers is 6.3%. 

The rising awareness about the availability of treatment options for diabetic ulcers, growing advancements in the treatment procedures, and increasing new product approvals are anticipated to propel the DU treatment market growth during the forecast period.

In 2017, the USFDA approved marketing of the Dermapace System, the first shock wave device intended to treat diabetic foot ulcers. Moreover, increasing incidences of mouth ulcer among the diabetic patients has resulted in a growing attention towards development of novel treatment options associated with diabetic mouth ulcers. According to the American Diabetes Association (ADA), patients with diabetes are more prone to gum diseases which can eventually affect the body’s blood sugar level, further giving rise to mouth ulcers.

Covid-19 Pandemic to Have an Adverse Effect on Market Growth

Diabetic ulcers treatment involves use of various medical device products in the form of dressings, wound care devices, and active therapies used at hospitals or home care settings. The emergence of the COVID-19 pandemic has resulted in slightly negative impact on the diabetic ulcers treatment market. This is attributed to the factors such as disruption of supply chain of medical devices such as shortages of raw materials, supply chain disruptions, unavailability of skilled wound care professionals, closure of OPDs, and delayed elective procedures due to lockdown implemented by various countries in response to the COVID-19. 

LATEST TRENDS

Increasing Adoption of Wound Care Devices for the Management of Diabetic Foot Ulceration

Diabetic foot ulcers are hard to heal. But the upcoming innovations in wound care devices will lead to a wider adoption across the world. The robust research activities implemented in bringing wound care products in the market have led to the rapid rise in the adoption of these products for enhancing the healing procedure of wounds associated with the diabetic ulcers. The new wound care system, EDX110, healed diabetic foot healed the wounds at a faster pace.

Strategic Investments to Enhance the Treatment Options

Several key players are currently focusing on investments to detect diabetic ulcers at an earlier stage to bring highly effective treatment options. In May 2019, NEO Tech and Podimetrics announced New Manufacturing Partnership to provide effective treatment solutions for diabetic foot ulcers.

DRIVING FACTORS

Increase in Prevalence of Diabetic Ulcer to Drive the Market

Globally, the incidences of diabetes are increasing at a rapid pace. According to an article published by the International Diabetes Federation (DFU) in 2019, an estimated 463 million people are suffering from diabetes and the number is expected to rise to 578 million by 2030. Thus, with the increase in the prevalence of diabetes, ulcers are anticipated to rise at a significant rate. Foot ulcer in diabetic people are more prevalent and is currently becoming a serious health concern across the globe. According to an article by the National Center for Biotechnology Information (NCBI) in 2019, the prevalence of diabetic foot ulcers in North America is 13% and the annual incidence of a diabetic foot ulcer is around 2-5%.

Advancements in Treatment Options to Provide Lucrative Growth Opportunities

Diabetic patients are seeking cost-effective treatment options for the management of diabetic ulcers. Recent advancements in treatment therapy are anticipated to play a vital role in fueling the market growth during the forecast period. The growing advancements in the biomaterials used for wood healing in diabetic foot ulcers such as poly (lactic-co-glycolic acid), or PLGA, collagen and chitosan, skin substitutes, extracellular matrix proteins, and miscellaneous therapeutic agents are expected to boost the market growth. 

Moreover, the rise in the number of players engaged in the development of the highly advanced product for the treatment of diabetic ulcers is likely to meet the growing demand for the urgent diabetic ulcer treatment. For, instances in 2019, Axio Biosolutions launched the next-generation wound care dressing product, MaxioCel made of chitosan for the treatment of diabetic foot ulcers, augmenting the market growth.

RESTRAINING FACTORS

High Cost of Ulcer Management & Unawareness about Treatment Options in Low Resource Countries to Restrict the Market Growth

Lack of awareness about the treatment options for ulcers due to diabetes and the presence of a handful of trained professionals in diabetic ulcers especially foot ulcer care in many less-developed countries, are likely to hinder the market growth. Moreover, the high cost of ulcer management is likely to restrict market growth. However, initiatives by government organizations in enhancing the knowledge about the availability of innovative treatment options in the market for diabetic ulcer management are likely to offer growth options. Geographical expansion product offerings by many key players are further to offer a valuable opportunity for the market to witness a significant sales growth.

SEGMENTATION

By Ulcer Type Analysis

Diabetic Foot Ulcer Segment to Account for the Highest Share during the Forecast Period

Based on the ulcer type, the market segments include foot ulcers, mouth ulcers, and others. The diabetic foot ulcers segment is further classified into neuropathic ulcers, ischemic ulcers, and neuro-ischemic ulcers. Among these, the diabetic foot ulcers segment accounted for the largest diabetic ulcer treatment market share in the year 2019. The segment is projected to continue its dominance throughout the forecast period. 

This is attributed to the growing incidences of foot ulcers in diabetic patients and the increasing penetration of effective treatment products for foot ulcer treatment in the market. Moreover, higher treatment costs and rise in prevalence of neuroischemic ulcer is likely to boost the diabetic foot ulcer segment growth rate during the forecast period.

The mouth ulcer segment is expected to witness a slow growth rate during the forecast period. Robust research activities conducted by many institutes and key players to bring effective treatment therapy for mouth ulcers due to diabetes are likely to provide lucrative opportunities for the management of oral lesions caused due to diabetes.

By Treatment Type Analysis

Wound Care Dressings Segment to Hold the Largest Market Share during the Forecast Period

In terms of treatment type, the market has been segmented into wound-care dressings, wound-care devices, active therapies, and others. Among them, the wound care dressing segment is anticipated to dominate the market. The launch of highly advanced wound care dressings for the treatment of diabetic foot ulcers and increasing adoption of these products is a primary factor that drives the wound care dressing segment's growth. In addition to this, the growing research activities for the development of innovative dressing materials for diabetic ulcer treatment is likely to increase the usage of wound care dressing at an accelerated speed.

The wound care devices segment is expected to witness a significant growth rate, owing to the introduction of innovative therapies including extracorporeal shock wave therapy for wound care. Moreover, the increasing number of regulatory approvals of wound care devices are anticipated to increase the adoption of new wound care devices during the forecast period. For instance, In April 2019, RLS Global announced the CE marking approval of its wound care product ChloraSolv targeting diabetic foot ulcers.

The active therapies segment includes skin grafts & substitutes, growth factors, and sealants. The growing application of skin graft & substitutes in the of diabetic ulcer treatment is anticipated to boost their adoption rates, further fueling the growth of the segment.

By End-User Analysis

Hospitals Segment to Continue Its Dominance during the Forecast Period

Based on end-user, the market segments include hospitals, clinics, ambulatory surgical centers, and home care settings. The hospital segment is anticipated to capture a dominant share in the market during the forecast period owing to the rise in the hospitalization rate and the rise in improving healthcare infrastructure.

The home care setting segment is expected to exhibit the fastest growth rate owing to the rise in the geriatric patient pool with and gradual shift in the preference of home care settings products for the treatment of diabetic ulcers, especially in high prevalent diabetic foot ulcer.

REGIONAL INSIGHTS

The outcomes based on our research methodology indicate North America to hold the largest share in the global market during the forecast period. The market in the North America was valued at USD 3.40 billion in the year 2019. North America, being technologically strong in terms of research and development, demonstrates indications of a strong foothold in the market. Moreover, there has been a significant rise in the adoption of wound care products and an increase in players in the region.

Europe region is expected to hold the second position in this market. Increased launch of innovative products by key players is majorly responsible for diabetic ulcer market expansion.

The market in Asia Pacific is expected to witness the highest growth rate in the coming years. The unprecedented rise in the diabetic population, along with the economic growth of many countries in Asia Pacific, is likely to contribute to the market growth in the region. The Latin America and the Middle East & Africa region is expected to register significant moderate growth owing to the rising unmet needs for cost-effective treatment options for diabetic foot ulcers. According to a cross-sectional study conducted by Paraíba State University, Brazil in 2015, the prevalence of oral lesion in was 78.4% in patients with diabetes mellitus Type 2, providing shreds of evidence that diabetes could have a negative impact on the oral health.

KEY INDUSTRY PLAYERS

Significant Players to Strongly Focus on Acquisitions to Strengthen Their Market Position

The leading players in the diabetic ulcer treatment market include Smith & Nephew, ConvaTec Group Plc, Coloplast Corp, and Mölnlycke Health Care AB. Introducing innovative treatment options for diabetic ulcers and expansion of sales channels are key strategies adopted by leading market players to maintain their dominant position in the market. Moreover, high emphasis on the strategic expansion of their product offerings through acquisitions & partnerships in the diabetic foot ulcer treatment is likely to provide a strong foothold in the global market

July 2018 - Mölnlycke Health Care AB acquired a German wound care products company, SastoMed GmbH., through this acquisition Mölnlycke Health Care AB aims to expandits wound care product portfoliowith the addition of SastoMed GmbH products including Granulox and Granudacyn for active and passive healing of chronic wounds such as diabetic foot ulcer.

LIST OF KEY COMPANIES PROFILED:

• Coloplast Corp(Denmark)


• Smith & Nephew(UK)


• ConvaTec Group Plc (UK)


• Mölnlycke Health Care AB.(Sweden)


• 3M (U.S.)


• Integra LifeSciences Corporation. (U.S.)


• Cardinal Health. (U.S.)


• Tissue Regenix (U.K)


• B. Braun Melsungen AG (Germany)

KEY INDUSTRY DEVELOPMENTS:

• December 2019 Orpyx Medical Technologies Inc. launched Orpyx SI Sensory Insoles with remote patient monitoring for the prevention of diabetic foot ulcer (DFU) and neuropathy-related ulcers.


• December 2017 SANUWAVE Health, Inc. received FDA approval for marketing of the Dermapace System, the first shock wave device intended to treat diabetic foot ulcers.

REPORT COVERAGE

The report offers qualitative and quantitative insights on diabetic ulcer treatment industries and the detailed analysis of market size & growth rate for all possible segments in the market.

Along with this, the report provides an elaborative analysis of the market dynamics, restraints, competitive landscape, regional analysis, and opportunities. It further offers the pipeline analysis of topical drugs, the regulatory scenario for key countries, key industry developments such as mergers & acquisitions, an overview of diabetic ulcers by critical countries, snapshots on the novel & upcoming innovative treatment options for diabetic ulcers.

Report Scope & Segmentation